Rationale for full-season dosing for passive antibody prophylaxis of respiratory syncytial virus

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 3, 2014, Pages 607-614

  Makari, Doris ^a   Checchia, Paul A ^b   DeVincenzo, John ^c,d  

^a MEDIMMUNE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^d LE BONHEUR CHILDREN'S MEDICAL CENTER   (United States)

Author keywords

Guidelines; Monthly dosing; Palivizumab; Preterm infants; Respiratory syncytial virus

Indexed keywords

PALIVIZUMAB; PLACEBO; MONOCLONAL ANTIBODY; VIRUS ANTIBODY;

ACTIVE IMMUNIZATION; AGE; ARTICLE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; HIGH RISK INFANT; HUMAN; INFECTION PREVENTION; INFECTION RATE; INFECTION RISK; NONHUMAN; PASSIVE IMMUNIZATION; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK ASSESSMENT; RISK FACTOR; SEASONAL VARIATION; VIRUS LOAD; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; PRESCHOOL CHILD; PROCEDURES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; CHILD, PRESCHOOL; HUMANS; IMMUNIZATION, PASSIVE; INFANT; PALIVIZUMAB; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TREATMENT OUTCOME;

EID: 84898427609     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.27426     Document Type: Article

References (46)

1. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2012:609-17.
2. Child Health BC. BC guidelines for RSV infection immunoprophylaxis: 2013-2014 RSV season. [cited 2014 Feb 20]. Available from: http://www. childhealthbc.ca/guidelines/category/17-rsv-immuno-prophylaxis-guidelines
3. Haller AA, Mitiku M, MacPhail M. Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV. J Gen Virol 2003; 84:2153-62; PMID:12867647; http://dx.doi.org/10.1099/vir.0.19079-0
4. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 2003; 112:1442-6; PMID:14654627; http://dx.doi.org/10.1542/peds.112.6.1442
5. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements - Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694-701; PMID:19736258; http://dx.doi.org/10.1542/peds.2009-2345
6. Solimano A, Kwan E. Revisiting palivizumab (PVZ) dosing recommendations based on published pharmacokinetics data. Presented at: Pediatric Academic Societies; April 28-May 1, 2012; Boston, MA.
7. Synagis® (palivizumab). Full Prescribing Information, MedImmune, LLC., Gaithersburg, MD, 2013.
8. Saari TN; American Academy of Pediatrics Committee on Infectious Diseases. Immunization of preterm and low birth weight infants. Pediatrics 2003; 112:193-8; PMID:12837889; http://dx.doi.org/10.1542/peds.112.1.193
9. Hamilton RG. Human IgG subclass measurements in the clinical laboratory. Clin Chem 1987; 33:1707-25; PMID:3311462
10. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:93-9; PMID:8989345; http://dx.doi.org/10.1542/peds.99.1.93
11. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
12. Bem RA, Domachowske JB, Rosenberg HF. Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 2011; 301:L148-56; PMID:21571908; http://dx.doi.org/10.1152/ajplung.00065.2011
13. DeVincenzo JP. A new direction in understanding the pathogenesis of respiratory syncytial virus bronchiolitis: how real infants suffer. J Infect Dis 2007; 195:1084-6; PMID:17357042; http://dx.doi.org/10.1086/512622
14. Welliver TP, Garofalo RP, Hosakote Y, Hintz KH, Avendano L, Sanchez K, Velozo L, Jafri H, Chavez-Bueno S, Ogra PL, et al. Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. J Infect Dis 2007; 195:1126-36; PMID:17357048; http://dx.doi.org/10. 1086/512615
15. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr., Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110-5; PMID:9493805; http://dx.doi.org/10.1097/00006454-199802000-00006
16. Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH Jr., Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:787-91; PMID:9779762; http://dx.doi.org/10.1097/00006454-199809000-00007
17. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7; http://dx.doi.org/10.1542/peds.102.3.531
18. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., Connor EM, Sondheimer HM; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40; PMID:14571236; http://dx.doi.org/10.1067/S0022-3476(03)00454-2
19. Centers for Disease Control and Prevention (CDC). Respiratory syncytial virus - United States, July 2007-June 2011. MMWR Morb Mortal Wkly Rep 2011; 60:1203-6; PMID:21900874
20. La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: A population pharmacokinetic analysis. Pulm Pharmacol Ther 2013; 26:666-71; PMID:23523663; http://dx.doi.org/10.1016/j.pupt.2013.03.007
21. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 2012; 56:4927-36; PMID:22802243; http://dx.doi.org/10.1128/AAC.06446-11
22. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28:511-7; PMID:18368063; http://dx.doi.org/10.1038/jp.2008.28
23. Berger J, Fensterheim L, O'Rourke J. The importance of Synagis compliance in preventing hospitalizations [abstract #2646]. Pediatr Res 2003; 53:468A-9A
24. Krilov LR, Weiner LB, Wade SW, Smith DM, Masaquel AS. Non-compliance with palivizumab and increased risk of respiratory syncytial virus hospitalization among a Medicaid population. Presented at: Pediatric Academic Societies Annual Meeting; April 28-May 1, 2012; Boston, MA.
25. Stewart DL, Ryan KJ, Seare JG, Pinsky B, Becker L, Frogel M. Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis. BMC Infect Dis 2013; 13: 334. PMID:23870086; http://dx.doi.org/10.1186/1471-2334-13-334
26. Fryzek JP, Martone WJ, Groothuis JR. Trends in chronologic age and infant respiratory syncytial virus hospitalization: an 8-year cohort study. Adv Ther 2011; 28:195-201; PMID:21327753; http://dx.doi.org/10.1007/s12325-010-0106-6
27. Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics 2013; 132:e341-8; PMID:23878043; http://dx.doi.org/10.1542/peds.2013- 0303
28. Holman RC, Curns AT, Cheek JE, Bresee JS, Singleton RJ, Carver K, Anderson LJ. Respiratory syncytial virus hospitalizations among American Indian and Alaska Native infants and the general United States infant population. Pediatrics 2004; 114:e437-44; PMID:15466069; http://dx.doi.org/10.1542/peds. 2004-0049
29. Law B, Macdonald N, Langley J, Mitchell I, Stephens D, Wang E, Robinson J, Boucher F, McDonald J, Dobson S. Severe respiratory syncytial virus infection among otherwise healthy prematurely born infants: What are we trying to prevent? Paediatr Child Health 1998; 3:402-4; PMID:20401222
30. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 2004; 22:275-84; PMID:15061677; http://dx.doi.org/10.2165/ 00019053-200422050-00001
31. Rossi GA, Medici MC, Arcangeletti MC, Lanari M, Merolla R, Paparatti UD, Silvestri M, Pistorio A, Chezzi C; Osservatorio RSV Study Group. Risk factors for severe RSV-induced lower respiratory tract infection over four consecutive epidemics. Eur J Pediatr 2007; 166:1267-72; PMID:17308898; http://dx.doi.org/10. 1007/s00431-007-0418-y
32. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31:5-9; PMID:21817948; http://dx.doi.org/10.1097/INF.0b013e31822e68e6
33. Vicente D, Montes M, Cilla G, Perez-Yarza EG, Perez-Trallero E. Hospitalization for respiratory syncytial virus in the paediatric population in Spain. Epidemiol Infect 2003; 131:867-72; PMID:14596527; http://dx.doi.org/10. 1017/S0950268803008926
34. Boyce TG, Mellen BG, Mitchel EF Jr., Wright PF, Griffin MR. Rates of hospitalization for respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000; 137:865-70; PMID:11113845; http://dx.doi.org/10.1067/ mpd.2000.110531
35. Carbonell X, Fullarton JR, Gooch KL, Figueras-Aloy J. The evolution of risk factors for respiratory syncytial virus-related hospitalisation in infants born at 32-35 weeks' gestational age: time-based analysis using data from the FLIP-2 study. J Perinat Med 2012; 40:685-91; PMID:23093079; http://dx.doi.org/ 10.1515/jpm-2011-0248
36. Carbonell-Estrany X, Quero J; IRIS Study Group. Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001; 20:874-9; PMID:11734767; http://dx.doi.org/10.1097/00006454-200109000-00010
37. Figueras-Aloy J, Carbonell-Estrany X, Quero J; IRIS Study Group. Case-control study of the risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born at a gestational age of 33-35 weeks in Spain. Pediatr Infect Dis J 2004; 23:815-20; PMID:15361718; http://dx.doi.org/10.1097/01.inf.0000136869.21397.6b
38. Figueras-Aloy J, Carbonell-Estrany X, Quero-Jiménez J, Fernández-Colomer B, Guzmán-Cabañas J, Echaniz-Urcelay I, Doménech-Martínez E; IRIS Study Group. FLIP-2 Study: risk factors linked to respiratory syncytial virus infection requiring hospitalization in premature infants born in Spain at a gestational age of 32 to 35 weeks. Pediatr Infect Dis J 2008; 27:788-93; PMID:18664927; http://dx.doi.org/10.1097/INF. 0b013e3181710990
39. Law BJ, Langley JM, Allen U, Paes B, Lee DS, Mitchell I, Sampalis J, Walti H, Robinson J, O'Brien K, et al. The Pediatric Investigators Collaborative Network on Infections in Canada study of predictors of hospitalization for respiratory syncytial virus infection for infants born at 33 through 35 completed weeks of gestation. Pediatr Infect Dis J 2004; 23:806-14; PMID:15361717; http://dx.doi.org/10.1097/01.inf.0000137568.71589.bd
40. Carbonell-Estrany X, Figueras-Aloy J, Law BJ; Infección Respiratoria Infantil por Virus Respiratorio Sincitial Study Group; Pediatric Investigators Collaborative Network on Infections in Canada Study Group. Identifying risk factors for severe respiratory syncytial virus among infants born after 33 through 35 completed weeks of gestation: different methodologies yield consistent findings. Pediatr Infect Dis J 2004; 23(Suppl):S193-201; PMID:15577573; http://dx.doi.org/10.1097/01.inf.0000144664.31888.53
41. Yeung CY, Hobbs JR. Serum-gamma-G-globulin levels in normal premature, post-mature, and "small-for-dates" newborn babies. Lancet 1968; 1:1167-70; PMID:4172289; http://dx.doi.org/10.1016/S0140-6736(68)91865-5
42. Correa-Rocha R, Pérez A, Lorente R, Ferrando-Martínez S, Leal M, Gurbindo D, Muñoz-Fernández MÁ. Preterm neonates show marked leukopenia and lymphopenia that are associated with increased regulatory T-cell values and diminished IL-7. Pediatr Res 2012; 71:590-7; PMID:22398700; http://dx.doi.org/10.1038/pr.2012.6
43. Friedrich L, Pitrez PM, Stein RT, Goldani M, Tepper R, Jones MH. Growth rate of lung function in healthy preterm infants. Am J Respir Crit Care Med 2007; 176:1269-73; PMID:17885265; http://dx.doi.org/10.1164/rccm.200703-476OC
44. McEvoy C, Venigalla S, Schilling D, Clay N, Spitale P, Nguyen T. Respiratory function in healthy late preterm infants delivered at 33-36 weeks of gestation. J Pediatr 2013; 162:464-9; PMID:23140884; http://dx.doi.org/10.1016/ j.jpeds.2012.09.042
45. Colin AA, McEvoy C, Castile RG. Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age. Pediatrics 2010; 126:115-28; PMID:20530073; http://dx.doi.org/10.1542/peds.2009-1381
46. Forbes ML, Kumar VR, Yogev R, et al. Association between palivizumab level and probability of respiratory syncytial virus admission to the pediatric intensive care unit among high-risk infants. Presented at: IDWeek; October 2-6, 2013; San Francisco, CA.